Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
|Conditions||carcinoma, non-small-cell lung, bronchial neoplasms, carcinoma, bronchogenic, lung diseases, lung neoplasms|
|Sponsor||Wenzhou Medical University|
|Start date||May 2016|
|End date||December 2017|
|Trial size||200 participants|
|Trial identifier||NCT02804100, 4241616009G|
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
dynamic changes of circulating tumor DNA in late stage NSCLC patients under Gefitinib treatment
time frame: 2 years
Male or female participants at least 18 years old.
Inclusion Criteria: - Provision of informed consent - Histologically confirmed stage IIIB/IV NSCLC. - Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) - Able to comply with the required protocol and followed-up procedures, and able to receive oral medications Exclusion Criteria: - Histologically confirmed small cell lung cancer or other metastatic tumors - Patient had received prior chemotherapy or EGFR-TKIs treatment - Patients who harbor Exon20 T790M mutation
|Official title||A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment|
Call for more information